Premium
Effect of administration of Eryngium carlinae on lipid profile in diabetes
Author(s) -
NoriegaCisneros Ruth,
CortésRojo Christian,
CalderónCortés Elizabeth,
ClementeGuerrero Mónica,
ManzoAvalos Salvador,
SaavedraMolina Alfredo
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.530.11
Subject(s) - pharmacology , traditional medicine , chemistry , administration (probate law) , lipid profile , diabetes mellitus , medicine , endocrinology , political science , law
People with diabetes are at risk of developing cardiovascular disease 2–4 times more than in the general population. Dyslipidemia is major cardiovascular risk factors in diabetes. Treatment of hyperlipidemia to reduce the cardiovascular risk is required in diabetic patients. Currently, the use of traditional medicine plants for treating disorders of lipid is gaining in importance; E. carlinae (EC) is one of them. The aim of this study was to assay the effect of administration of extract of EC on lipid profile on diabetic rats. Male Wistar rats were used. Diabetes was induced by a single injection (ip) of streptozotocin (45 mg/kg). Rats were divided into four groups. Group I: control, Group II: control + EC (100 mg/kg of body weight), Group III: diabetic, Group IV: diabetic + EC (100 mg/kg of body weight). The extract was administered orally for 20 days at the end of treatment the rats were sacrificed and blood was collected. The levels of glucose, triglycerides, total cholesterol, HDL‐cholesterol and LDL‐cholesterol were assayed in the serum. Diabetes decreases blood levels of HDL‐cholesterol in serum and found that the treatment with EC restored these levels and reduce levels of LDL‐cholesterol. The administration of EC has no effect on glucose levels in diabetic rats. Although EC has no effect on one of the main characteristics of diabetes such as hyperglycemia, if it improves the lipid profile in diabetes, therefore may be used as a complementary treatment for this condition. Authors appreciate the financial support of CIC‐UMSNH (2.16, 2009) grant and CONACYT (144250 to ASM during its sabbatical).